NORETHINDRONE AND MESTRANOL Drug Patent Profile

When do Norethindrone And Mestranol patents expire, and what generic alternatives are available?

Norethindrone And Mestranol is a drug marketed by Watson Labs and is included in two NDAs.

The generic ingredient in NORETHINDRONE AND MESTRANOL is mestranol; norethindrone. There is one drug master file entry for this compound. Additional details are available on the mestranol; norethindrone profile page.

Summary for NORETHINDRONE AND MESTRANOL

US Patents:	0
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	4
Patent Applications:	89
DailyMed Link:	NORETHINDRONE AND MESTRANOL at DailyMed

US Patents and Regulatory Information for NORETHINDRONE AND MESTRANOL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Watson Labs	NORETHINDRONE AND MESTRANOL	mestranol; norethindrone	TABLET;ORAL-21	070758-001	Jul 1, 1988		DISCN	No	No
Watson Labs	NORETHINDRONE AND MESTRANOL	mestranol; norethindrone	TABLET;ORAL-28	070759-001	Jul 1, 1988		DISCN	No	No

Norethindrone and Mestranol Market Dynamics, Patent Status, and Financial Trajectory

Last updated: September 9, 2026

Norethindrone and mestranol is an obsolete combined oral contraceptive combination. The principal historical products were Norinyl and related norethindrone-mestranol tablets, generally containing norethindrone 1 mg with mestranol 0.05 mg or lower-dose variants. The combination has lost commercial relevance because mestranol-based contraceptives were replaced by products using ethinyl estradiol, lower-dose estrogen regimens, progestin-only products, and newer delivery systems.

The product has no meaningful current patent exclusivity, no active biologic or biosimilar issue, and no identifiable standalone revenue stream. Any remaining market activity is limited to legacy inventory, historical references, or niche availability outside major regulated markets.

What is norethindrone and mestranol?

Norethindrone and mestranol is an oral estrogen-progestin contraceptive.

Component	Pharmacologic role	Commercial relevance
Norethindrone	Synthetic progestin that suppresses ovulation and changes cervical mucus and endometrial receptivity	Still used in several modern contraceptive products
Mestranol	Ethinyl estradiol prodrug that provides estrogenic activity after conversion	Largely displaced by direct ethinyl estradiol formulations
Historical dosage	Commonly 1 mg norethindrone plus 0.05 mg mestranol	Associated with older high-estrogen oral contraceptives
Principal historical brands	Norinyl and related products	No longer a major U.S. commercial franchise

Mestranol was used in early generations of combined oral contraceptives. It has substantially lower commercial presence than ethinyl estradiol, which became the standard estrogen component in most later combined pills.

Which companies marketed norethindrone and mestranol?

Historical marketing involved companies associated with the early oral contraceptive market, including Syntex and Ortho Pharmaceutical. Brand ownership and manufacturing arrangements changed over time through acquisitions, licensing, and product discontinuations.

Norinyl was one of the best-known product names associated with norethindrone and mestranol. Ortho-Novum products were also historically associated with norethindrone-based contraceptive formulations, although product-specific compositions and labeling changed over time.

The commercial model was typical of first-generation oral contraceptives:

1. Initial innovation centered on hormonal composition and oral delivery.
2. Brand value was supported by physician familiarity, distribution, and regulatory approvals.
3. Patent and regulatory barriers declined as the products aged.
4. Later products competed through lower estrogen exposure, improved tolerability, simplified dosing, and broader generic availability.

What was the FDA regulatory status of norethindrone and mestranol?

Norethindrone and mestranol products were approved as prescription oral contraceptives before the modern generic-drug framework became central to pharmaceutical competition. Historical labeling addressed prevention of pregnancy and included estrogen-related contraindications and warnings.

The combination is not a modern new-drug franchise. It does not have current U.S. regulatory exclusivity comparable to a recently approved product. Current FDA contraceptive practice is concentrated on products containing ethinyl estradiol, norethindrone, levonorgestrel, drospirenone, norgestimate, desogestrel, or progestin-only agents.

The FDA’s current product databases and labeling systems are the relevant sources for determining whether a specific product remains approved, marketed, or discontinued. Product availability should not be inferred solely from the continued existence of historical labeling or drug references. [1][2]

When did norethindrone and mestranol lose exclusivity?

Norethindrone and mestranol lost meaningful exclusivity decades ago. The products were commercialized in the 1960s, placing any original composition, formulation, or use patents well beyond their ordinary 20-year patent terms under modern U.S. patent law.

The practical exclusivity timeline is:

Period	Commercial position
1960s	Early combined oral contraceptive commercialization
1970s to 1980s	Established branded product with expanding contraceptive competition
1980s to 1990s	Increasing substitution by lower-dose and ethinyl estradiol products
1990s to 2000s	Generic and legacy-product pressure; declining strategic importance
Current period	No material branded exclusivity or innovative-product protection

The product predates the Hatch-Waxman framework, so modern Orange Book patent litigation is not central to its commercial history. Any historical patents covering norethindrone, mestranol, specific ratios, or tablet formulations would have expired long ago.

What patents protect norethindrone and mestranol?

No commercially material unexpired U.S. patent estate protects the historical norethindrone-mestranol combination.

Potential historical patent categories included:

• Steroidal active ingredients and synthetic intermediates
• Combination compositions containing a progestin and estrogen
• Oral tablet formulations
• Contraceptive methods of use
• Manufacturing and crystallization processes
• Packaging and dosage regimens

Those categories do not create present-day exclusivity. Patent protection for early oral contraceptives is expired, and the active ingredients are not protected by current composition-of-matter rights in the way a newly discovered chemical entity would be.

What formulations are protected by patents?

No currently relevant proprietary formulation moat is associated with the historical combination. Conventional immediate-release tablets are technically straightforward to manufacture. The product does not depend on a complex delivery system, device, depot technology, transdermal platform, or controlled-release formulation.

Any modern attempt to commercialize the combination would likely require regulatory compliance, manufacturing validation, quality controls, and commercial distribution rather than an inventive patent barrier.

How many patents cover norethindrone and mestranol?

The historical patent count cannot be equated with current market protection. Patent families may have covered the active ingredients, synthesis routes, combinations, and contraceptive methods, but expired patents do not block generic manufacture.

For commercial analysis, the relevant count is:

Patent category	Current blocking value
Active-ingredient patents	None material
Combination patents	None material
Tablet formulation patents	None material
Method-of-use patents	None material
Manufacturing patents	Potentially relevant only if a new process is independently patented
Orange Book-listed patents	No commercially significant current estate identified

A company could seek protection for a genuinely novel formulation, delivery system, or manufacturing process. Such a patent would protect the new technology, not the historical norethindrone-mestranol combination itself.

What is the Orange Book status of norethindrone and mestranol?

The combination has no meaningful current Orange Book position comparable to active branded contraceptive products. The Orange Book is relevant only to the extent that a specific marketed product remains approved and has listed patents or exclusivity.

Historical products that have been discontinued do not create a continuing commercial barrier. A generic applicant seeking approval for a currently listed reference product would evaluate the product’s regulatory status, labeling, bioequivalence requirements, and any listed patents. For an obsolete or discontinued product, the principal barrier may be regulatory and commercial feasibility rather than patent risk. [1]

Are there Paragraph IV challenges involving norethindrone and mestranol?

No current commercially significant Paragraph IV campaign is associated with the historical norethindrone-mestranol combination.

Paragraph IV litigation is generally relevant when:

• A branded reference product remains commercially important.
• The reference product has listed patents.
• A generic applicant seeks approval before patent expiry.
• The expected market supports litigation expense.

Those conditions do not describe the current norethindrone-mestranol market. Any historical generic disputes would have limited present value because the relevant patents and commercial positions have aged out.

Does norethindrone and mestranol face biosimilar risk?

No. Biosimilar risk is not applicable because norethindrone and mestranol are chemically synthesized small molecules, not biologic medicines.

The relevant competitive risks are:

• Generic substitution
• Product discontinuation
• Limited manufacturing capacity
• Declining physician familiarity
• Replacement by ethinyl estradiol products
• Patient preference for newer oral, transdermal, vaginal, injectable, or implantable options

The FDA’s abbreviated new drug application pathway, rather than the biosimilar pathway, is the relevant framework for a conventional generic version. [3]

How does norethindrone and mestranol compare with modern contraceptives?

Attribute	Norethindrone and mestranol	Modern norethindrone and ethinyl estradiol products	Progestin-only products
Estrogen component	Mestranol	Usually ethinyl estradiol	None
Historical estrogen exposure	Relatively high by current standards	Often lower-dose	No estrogen-related exposure
Commercial position	Legacy or discontinued	Active generic and branded markets	Active and expanding
Patent protection	Expired	Mostly expired at molecule level; some formulation or use patents may exist	Product-specific
Main competitive advantage	Historical familiarity	Broad availability and established prescribing	Avoidance of estrogen in selected patients
Delivery options	Oral tablet	Oral tablet, patch, ring depending on product	Pill, injection, implant, intrauterine system

The key commercial distinction is that norethindrone remains relevant as a progestin, while mestranol has largely disappeared from mainstream contraceptive development.

What is the financial trajectory of norethindrone and mestranol?

The financial trajectory is one of long-term erosion rather than growth.

Revenue trajectory

No major pharmaceutical company currently reports standalone revenue for norethindrone and mestranol. The combination is too old and commercially marginal to appear as a separate reporting segment in public company filings.

Its historical revenue path likely followed four stages:

1. Early growth after oral contraception entered routine medical use.
2. Mature branded revenue supported by prescription volume and physician adoption.
3. Decline as lower-dose estrogen products and generic alternatives expanded.
4. Near-total erosion after product discontinuations and portfolio rationalization.

Revenue exposure today is effectively immaterial for large pharmaceutical companies. Any residual value would arise from contract manufacturing, regional distribution, or legacy product sales rather than brand pricing power.

Margin trajectory

Margins declined as the market shifted from differentiated branded products to commodity-like generic supply. The active ingredients are established, conventional tablets are inexpensive to produce, and there is no current premium technology supporting high pricing.

A remaining supplier could face:

• Small and irregular order volumes
• Higher unit costs from low manufacturing scale
• Regulatory maintenance costs
• Limited pharmacy demand
• Inventory and discontinuation risk
• Competition from better-known alternatives

What generic launch risks exist?

A new generic launch would face low patent risk but uncertain commercial returns.

Risk area	Assessment
Patent blockage	Low
Regulatory pathway	Conventional generic pathway if an approved reference product is available
Bioequivalence	Manageable for an immediate-release tablet
Manufacturing complexity	Low to moderate
Market size	Small and declining
Pricing power	Low
Reference-product availability	Potentially limiting
Distribution economics	Weak unless tied to a broader contraceptive portfolio

The principal risk is not a patent injunction. It is insufficient demand to justify development, regulatory filing, commercial inventory, and pharmacovigilance costs.

What manufacturing and IP barriers affect the product?

Manufacturing barriers are limited for a standard tablet but are not zero. A supplier must maintain validated analytical methods, active-ingredient sourcing, content uniformity, dissolution performance, stability data, and compliant packaging.

The most relevant operational constraints are:

• Reliable sourcing of norethindrone and mestranol
• Control of low-dose hormone uniformity
• Stability of the estrogen component
• Validated combination assays
• Batch-release testing
• Regulatory documentation for an old or discontinued reference product

These are execution barriers rather than durable intellectual-property barriers.

What is the competitive landscape?

The competitive landscape is dominated by replacement products, not direct mestranol competitors.

Relevant classes include:

• Norethindrone and ethinyl estradiol tablets
• Levonorgestrel and ethinyl estradiol tablets
• Norgestimate and ethinyl estradiol tablets
• Drospirenone and ethinyl estradiol products
• Progestin-only norethindrone tablets
• Long-acting reversible contraceptives
• Transdermal patches and vaginal rings
• Emergency contraception products

The market has shifted toward lower-dose estrogen, broader formulation choice, improved tolerability, and patient-specific risk management. That shift structurally disadvantages mestranol-based products.

What patent litigation and settlement agreements affect the product?

No current material patent litigation or settlement activity is associated with norethindrone and mestranol. The product’s commercial decline occurred through aging patents, generic competition, substitution, and discontinuation rather than a current litigation cycle.

There is no apparent settlement-driven launch schedule comparable to those seen for high-revenue branded drugs. Any historical agreements would have limited effect on present valuation.

Key Takeaways

• Norethindrone and mestranol is a legacy combined oral contraceptive combination.
• Norinyl is the principal historical brand associated with the combination.
• Mestranol has largely been replaced by ethinyl estradiol.
• The historical patent estate is expired and has no meaningful current blocking value.
• No current Orange Book, Paragraph IV, biosimilar, or litigation issue materially affects the product.
• Standalone revenue is no longer separately reported by major pharmaceutical companies.
• Generic manufacturing is technically feasible, but market demand and commercial returns are weak.
• Norethindrone remains commercially relevant in newer contraceptive products, while mestranol does not.
• Any renewed commercial opportunity would depend on a new formulation, delivery system, or differentiated regulatory strategy, not the old combination itself.

FAQs

Is Norinyl still available in the United States?

Norinyl is a historical product and is not a material current U.S. contraceptive brand. Availability should be determined through current FDA product records and commercial pharmacy listings rather than historical drug references.

Is mestranol the same as ethinyl estradiol?

No. Mestranol is converted in the body to ethinyl estradiol, but the two are distinct active pharmaceutical ingredients with different historical use patterns and labeling.

Can a company still manufacture norethindrone and mestranol?

A company could pursue manufacturing subject to applicable FDA or foreign regulatory requirements, approved-product availability, quality standards, and commercial viability. Expired patents would generally not prevent manufacture.

Why did mestranol disappear from contraceptive products?

Mestranol was displaced by ethinyl estradiol and other hormonal approaches as developers pursued lower-dose regimens, updated safety profiles, improved prescribing flexibility, and more competitive formulations.

Does norethindrone and mestranol have investment value?

The legacy combination has little direct investment value as a standalone product. Any value would likely reside in manufacturing rights, regional distribution, or a new product platform rather than the historical drug itself.

References

1. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

2. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

3. U.S. Food and Drug Administration. (2024). Generic drug facts. https://www.fda.gov/drugs/generic-drugs/generic-drug-facts

4. U.S. Food and Drug Administration. (2019). Birth control guide. https://www.fda.gov/consumers/free-publications-women/birth-control-guide

5. U.S. Patent and Trademark Office. (2024). Patent term adjustment and patent term extension. https://www.uspto.gov/patents/laws/patent-term-adjustment-patent-term-extension-reissue-grace-period-partners